Trials and Tribulations of Evidence-Based Medicine: The Case of Alzheimer Disease Therapeutics

Sackett DL Rosenberg WM Gray JA Evidence based medicine: What it is and what it isn't. BMJ. 1996;312:71–72.

Godloe F. Milestones on the long road to knowledge. BMJ. 2007;334 (Suppl 1):S2–S3.

Gorman C. Are doctors just playing hunches? Time Magazine. 2007;169 (9):40–43.

Hunink MGM . Does evidence-based medicine do more good than harm? BMJ. 2004;329:1051.

Marchetti P Cantor RM Donnell RW Does “evidence-based medicine” diminish the physician's role? Medscape Med Med Students [Internet]. 2007 [cited 2007 Jan 17];9(1). Available from: http://www.medscape.com/viewarticle/549329.

Holmes D Murray SJ Perron A Deconstructing the evidence-based discourse in health sciences: Truth, power and fascism. Int J Evid Based Healthc. 2006;4:180–186.

Seow D Gathier S. Pharmacotherapy of Alzheimer's disease. Can J Psychiatry. 2007;52(10):620–629.

Herrmann N Lanctôt KL . Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry. 2007;52(10):630–646.

Lanctôt KL Herrmann N Yau KK Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A meta-analysis. CMAJ. 2003;169:557–564.

Ritchie CW Ames D Clayton T Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry. 2004;12:358–369.

Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75:677–685.

Takeda A Loveman E Clegg A A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry. 2006;21:17–28.

Kaduszkiewicz H Zimmermann T Beck-Bornholdt HP Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ. 2005;331:321–327.

Lam RW Kennedy SH . Using metaanalysis to evaluate evidence: Practical tips and traps. Can J Psychiatry. 2005;50:167–174.

Jadad AR Cook DJ Browman GP . A guide to interpreting discordant systematic reviews. CMAJ. 1997;156:1411–1416.

Gill SS Bronskill SE Mamdani M Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004;11:e274–285.

Lanctôt KL Herrmann N LouLou MM . Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci. 2003;28:13–26.

Thompson S Lanctôt KL Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf. 2004;3:425–440.

Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: A review, summary, and critique. Am J Geriatr Psychiatry. 2001;9:361–381.

Snowden M Sato K Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: A review of the literature. J Am Geriatr Soc. 2003;51:1305–1317.

Opie J Rosewarne R O'Connor DW . The efficacy of psychosocial approaches to behaviour disorders in dementia: A systematic literature review. Aust N Z J Psychiatry. 1999;33:789–799.

Verkaik R van Weert JC Francke AL . The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: A systematic review. Int J Geriatr Psychiatry. 2005;20:301–314.

Livingston G Johnston K Katona C Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162:1996–2021.

Cohen-Mansfield J Mintzer JE . Time for change: The role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord. 2005;19:37–40.

Herrmann N Lanctôt KL . Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19:91–103.

Schneider LS Dagerman KS Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–1943.

US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry. Information program on clinical trials for serious or life-threatening diseases and conditions [Internet]. Rockville (MD): CDER; [cited 2007 Jun 22]. Available from: http://www.fda.gov/cder/guidance/4856fnl.htm.

Ioannidis JP Evans SJ Gotzsche PC Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med. 2004;141:781–788.

Haynes RB Devereaux PJ Guyatt GH . Clinical expertise in the era of evidence-based medicine and patient choice. Evid Based Med. 2007;7:36–38.

Woolf SH Grol R Hutchinson A Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527–530.